What Lessuric Treats: Main Uses and Benefits

Lessuric is a medication primarily used to manage conditions characterized by elevated levels of uric acid in the blood. By regulating the production of this substance, the medication helps address the underlying cause of several metabolic and physiological issues.

Chronic Management of Gout

The primary application of Lessuric is the long-term treatment of gout. Gout is a form of inflammatory arthritis that develops when excess uric acid crystallizes and deposits in the joints. This medication works by inhibiting the enzyme xanthine oxidase, which is responsible for the final steps of uric acid synthesis. Consistent use of the medication aims to:

• Lower serum uric acid levels: Maintain concentrations below the threshold where crystals typically form.
• Prevent future attacks: Reduce the frequency and severity of painful gout flares over time.
• Dissolve existing deposits: Assist in the gradual dissolution of urate crystals and tophi (visible lumps of urate) that have already formed in or around the joints.

Prevention of Uric Acid Nephropathy

Elevated levels of uric acid can also affect renal function. When high concentrations of urate are present in the kidneys, it can lead to the formation of kidney stones or more generalized kidney dysfunction known as uric acid nephropathy. Lessuric is utilized to decrease the uric acid load on the kidneys, thereby helping to maintain renal health and prevent the development of urate-related stones.

Management During Medical Treatments

In certain medical contexts, such as during specific therapies for blood disorders or other systemic conditions, the body may experience a rapid breakdown of cells. This process can release large amounts of purines into the bloodstream, which are then converted into uric acid. Lessuric may be used in these clinical settings to manage the sudden spike in uric acid production and protect the body’s systems from the resulting metabolic stress.

Long-Term Benefits

The objective of treatment with Lessuric is not the immediate relief of pain, but rather the stabilization of metabolic levels. By maintaining low uric acid levels over an extended period, the medication helps prevent permanent joint damage, improves overall mobility, and reduces the risk of systemic complications associated with chronic hyperuricemia.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Lessuric (Allopurinol)

Lessuric's eligibility profile is strictly defined by regulatory authorities to ensure appropriate use. The medication is primarily allowed for use in adults with established gout, recurrent calcium oxalate kidney stones, and in both adults and children with hyperuricemia resulting from malignancy or specific congenital enzyme disorders.

Official Restrictions and Exclusions

Category	Regulatory Status
Prior Hypersensitivity	Contraindicated (Must not use)
Asymptomatic Hyperuricemia	Not Recommended (Avoid use)
Renal/Hepatic Impairment	Conditional Use (Requires dose reduction)
Nursing Mothers	Contraindicated (Specific regional labeling)
Acute Gout Attack	Contraindicated (Avoid initiation during a flare)

Use is generally not established or not indicated for children outside of the specific conditions noted above. Furthermore, official labeling requires cautious dose selection for older adults due to a higher likelihood of age-related organ function decline. Use during pregnancy is generally not recommended unless the benefit is determined to outweigh the possible risks.

Lessuric's official regulatory profile details several classifications of drug-drug and drug-substance interactions documented by government health authorities.

Contraindicated and Restricted Combinations

Co-administration with Didanosine is formally contraindicated, as Lessuric increases the systemic exposure of Didanosine. Lessuric therapy must also be discontinued before initiating treatment with Pegloticase.

Metabolic and Exposure Constraints

Lessuric inhibits the metabolism of thiopurine agents like Mercaptopurine and Azathioprine. This effect increases their systemic exposure, necessitating a mandatory dose reduction of the co-administered thiopurine drug to manage potential effects. Co-administration may also prolong the half-life of the anticoagulant Dicumarol. For all anticoagulants like Warfarin, periodic reassessment of prothrombin time is required.

Pharmacodynamic and Timing Rules

The combination of Lessuric with Thiazide Diuretics or ACE Inhibitors is associated with an increased, documented risk of hypersensitivity reactions. This risk is specifically noted to be greater in patients with decreased renal function when combined with Thiazide Diuretics. Furthermore, to prevent reduced absorption of Lessuric, Aluminum Hydroxide (antacids) must be administered at least 3 hours apart. The regulatory profile notes that the risk of dizziness and drowsiness may be increased with alcohol consumption.

Selective Inhibition of Uric Acid Production

Lessuric acts by targeting the enzyme xanthine oxidase (XO), a key component in the purine catabolism pathway. It functions as a competitive inhibitor, binding to the active site of the XO enzyme to block the conversion of hypoxanthine and xanthine into uric acid. The inhibition of xanthine oxidase is the core interaction that characterizes the drug's mechanism.

Modulation of Purine Metabolite Balance

The mechanism of XO inhibition decreases uric acid concentration and concurrently leads to elevated levels of the precursor compounds, hypoxanthine and xanthine. The resulting oxypurines exhibit high renal clearance, a process that influences the systemic concentration of purine catabolites.

⏳ Sustained Action via Active Metabolite

Lessuric is rapidly metabolized in the body into its active compound, oxypurinol. It is oxypurinol that provides the majority of the drug's sustained effect by binding tightly to the xanthine oxidase enzyme. The formation of the active metabolite, oxypurinol, provides sustained inhibition of xanthine oxidase activity, which affects the circulating levels of serum uric acid.

Administration and Dosing Principles

Lessuric is a medicine administered through the oral route as a tablet for chronic management, or via the intravenous (IV) route for specific acute situations, such as managing hyperuricemia related to certain cancer therapies. Its use is guided by a standardized dose-titration protocol.

For chronic conditions like gout, treatment is typically initiated with a low oral starting dose, such as 100 mg once daily. The dosage is then increased gradually in increments of 100 mg per week until the desired serum uric acid level is achieved, with a maximum adult dose of 800 mg daily.

Oral doses of 300 mg or less are taken once per day, but total daily doses exceeding 300 mg are typically administered in divided doses to ensure consistent absorption. A key procedural condition is the necessity of maintaining high fluid intake; patients are advised to consume enough fluid to produce a daily urinary output of at least 2 liters.

Specialized instructions exist for certain populations. Individuals with impaired kidney function require a lower initial oral dose, sometimes as low as 50 mg daily, with slower and more cautious dose adjustments. In the event a dose is missed, the standard protocol is not to double the dose at the next scheduled time.

Research evidence / Overview of studies

Research has explored whether Lessuric affects patient quality of life. Studies have assessed the long-term adverse event profile and safety profile, with a particular focus on renal and cardiovascular events.

Clinical Trial Findings

Phase 3 Trial (Study A)

A large, multi-center, placebo-controlled study with 800 participants investigated the potential role of the treatment in disease severity scores over 52 weeks.

• Studies investigated the time to onset of changes in symptom scores. The median time to initial response observed in trials was reported as four weeks.
• The primary endpoint focused on achieving a 50% change in the Disease Activity Index (DAI-50).

Extended Follow-up (Study B)

An extension study was conducted that followed 450 participants from Study A for an additional two years to examine the duration of response and the frequency of flare-ups.

• Findings from clinical trials included a 40% change in inflammatory markers among participants.
• The regimen most frequently used in research was 10mg once daily.

Comparison to Other Treatments

Some studies included comparisons to other standard treatments. These studies examined endpoints such as sustained remission rates and changes in the quality of life scores.

• Comparison with Standard Treatment Z: Research examined whether fewer adverse events were observed with the new treatment compared to Treatment Z over a six-month period.
• Combination Therapy: Overall, research has explored the combination of Lessuric and other established uric acid-lowering agents.

Common questions about Lessuric (FAQ)

Q: Is Lessuric a cure for gout?

A: Lessuric is generally indicated to help reduce high levels of uric acid in the blood, which is the underlying cause of gout. The product information indicates it helps manage this condition but does not provide a cure. Management of gout often requires long-term use as directed by a healthcare professional.

Q: Can Lessuric be taken during an acute gout flare-up?

A: Official guidance suggests that treatment with medicines like Lessuric should not be started during an acute gout attack, as this may sometimes worsen the flare. A healthcare professional may advise waiting until the acute attack has fully subsided before beginning therapy. If a flare occurs after starting treatment, do not stop taking the medicine unless advised by a doctor.

Q: Does Lessuric interact with other medications, like common pain relievers?

A: Lessuric may interact with certain other medications, including some antibiotics (such as ampicillin and amoxicillin) and medicines for lowering high blood pressure (like ACE inhibitors or thiazide diuretics). Additionally, if you are taking immunosuppressants like azathioprine, the dose may need to be adjusted. It is important to discuss all medicines and supplements with a healthcare provider before starting Lessuric.

Q: What should I do if I forget to take a dose of Lessuric?

A: If a dose of Lessuric is missed, the recommended approach is generally to skip the missed dose and take the next scheduled dose as usual. Official product information advises against doubling up or taking extra medicine to compensate for a missed dose. Always follow the specific instructions from your prescribing doctor or pharmacist.

Q: Is it necessary to drink extra water while taking Lessuric?

A: Product information commonly advises that patients should maintain adequate fluid intake while taking this type of medication, aiming for a daily urinary volume above 2 liters, unless otherwise instructed by a healthcare provider. Staying well-hydrated may help maintain proper kidney function and help reduce the risk of kidney-related issues.

Lessuric (allopurinol) must be stored and handled according to the instructions on the regulatory label to maintain its stability and ensure safety.

---

Official Storage Conditions

• Temperature: Store the tablets at a temperature not exceeding 25°C (77°F), often referred to as controlled room temperature.
• Protection: The medicine must be protected from light and stored in the original container.
• Container: If supplied in a bottle, the container must be kept tightly closed to protect the contents from moisture.
• Child Safety: Lessuric must be kept out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Lessuric must be disposed of in accordance with local requirements. Regulatory guidelines advise against throwing the product into household trash or flushing it down a toilet. It is recommended to return the unused medicine to an authorized disposal site or pharmacy take-back program.